Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385293 · ClinicalTrials.gov registry record · Phase 2
BKM120 in Metastatic Castration-resistant Prostate Cancer
A Phase 2 study, sponsored by Andrew J. Armstrong, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01385293 is a Phase 2 study that was terminated before completion, run by Andrew J. Armstrong, MD. The registered enrollment target is 30 participants.
The verdict
NCT01385293, a Phase 2 study, was terminated before completion, sponsored by Andrew J. Armstrong, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This protein is found in normal cells and in cancer cells, but often in many cancer cells this protein is overactive. Inhibiting the protein may slow the growth of prostate cancer but this has not been tested yet in men with prostate cancer.
Interventions
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385293
The ClinicalTrials.gov registry entry for NCT01385293 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew J. Armstrong, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM120 is the first listed.
NCT01385293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01385293 about?
NCT01385293 is a clinical study titled "BKM120 in Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This protein is found in normal cells and in cancer cells, but often in many cancer cells this protein is overactive. Inh...
What is the current status of trial NCT01385293?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01385293?
The interventions under investigation include: BKM120 (DRUG).
Who is sponsoring clinical trial NCT01385293?
This trial is sponsored by Andrew J. Armstrong, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.